Abstract
Inflammatory bowel disease (IBD) clinical trials face a recruitment crisis. This is attributable to multiple individual trials competing for the same pool of participants, growing sample size demands and the increased availability of licensed alternative options for many potential participants. We need phase II trials that are more efficient both in design and in outcomes measured in order to deliver earlier and more precise answers, rather than simply offering a crude preview of what a subsequent phase III trial might look like.